Skip to main content
PMC home page
Rheumatology (Oxford, England) logoLink to Rheumatology (Oxford, England)
. 2017 May 22;56(6):1049. doi: 10.1093/rheumatology/kex218

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales

Eoghan M McCarthy 1, Emily Sutton 2, Stephanie Nesbit 2, Ben Parker 1,3, David Jayne 4, Bridget Griffiths 5, David A Isenberg 6, Anisur Rahman 6, Caroline Gordon 7,8, David P D’Cruz 9, Benjamin Rhodes 10, Peter Lanyon 11, Edward M Vital 12,13, Chee-Seng Yee 14, Christopher J Edwards 15,16, Lee-Suan Teh 17, Mohammed Akil 18, Neil J McHugh 19,20, Asad Zoma 21, Ian N Bruce 1,2,✉; on behalf of the British Isles Lupus Assessment Group Biologics Register
PMCID: PMC6790502  PMID: 28549192

Rheumatology, 10.1093/rheumatology/kex044

The title of the above paper has been adapted after publication ahead of print. The original title of The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence has been adapted to The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.

This has been corrected online and in print.

Articles from Rheumatology (Oxford, England) are provided here courtesy of Oxford University Press

RESOURCES